Join to View Full Profile
1321 Upland Dr# 4129Houston, TX 77043
Dr. Argiris is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Athanassios Argiris is an oncologist with subspecialties in head and neck cancer, hematologic oncology, and thoracic cancer. He completed his medical education at the University of Athens, followed by an internal medicine residency at Icahn School of Medicine at Mount Sinai/Beth Israel, and a fellowship in medical oncology at Yale-New Haven Medical Center. He has expertise in head and neck and thoracic oncology and has contributed several publications, notably on combined modality therapy of head and neck cancer, immunotherapy and gene-expression subtypes in head and neck cancer. His work has been published in journals like Journal of Clinical Oncology, JAMA, Annals of Oncology and Clinical Cancer Research. Dr. Argiris has also been involved in numerous clinical trials, including studies on recurrent head and neck cancer, advanced non-small cell lung cancer and high-risk salivary gland malignancies. He earned the CMS Meaningful Use Stage 1 Certification in 2013 and is a Fellow of the American College of Physicians since 2005.
Education & Training
Yale-New Haven Medical CenterFellowship, Medical Oncology, 1999
Icahn School of Medicine at Mount Sinai/Beth IsraelResidency, Internal Medicine, 1994 - 1997
University of AthensClass of 1990
Certifications & Licensure
OH State Medical License Current
PA State Medical License 2005 - 2026
TX State Medical License 2011 - 2026
IL State Medical License 2000 - 2005
CT State Medical License 1997 - 2000
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Fellow (FACP) American College of Physicians, 2005
Clinical Trials
- Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Advanced Cancer of the Mouth, Pharynx, or Larynx Start of enrollment: 1999 Aug 01
- Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced and/or Recurrent Head and Neck Cancer Start of enrollment: 1999 Aug 01
- Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer Start of enrollment: 2002 Nov 19
Publications & Presentations
PubMed
- Different Pattern of Treatment Failure After Chemoradiation Between p16+ and p16- Patients Affected by Oropharyngeal Carcinoma.Riccardo Gili, Paolo Bossi, Luca Lalli, Lisa Francesca Linda Licitra, Marta Maddalo
Head & Neck. 2026-08-01 - Standardization of objectives and response criteria for neoadjuvant immunotherapy in resectable squamous cell carcinoma of the head and neck.Carlo Resteghini, Athanassios Argiris, Pierre Blanchard, Irene Braña, Anna Maria Camarda
Cancer Treatment Reviews. 2026-07-01 - 2 citationsExtracellular Matrix-MYCAF Signatures Correlate with Resistance to Neoadjuvant aPD-L1 Immune Checkpoint Inhibition with Durvalumab + Metformin in HPV+ HNSCC.Pablo Llerena, Hani Samarah, Kathryn Nunes, Zhao Lin, Kelly Bridgham
Clinical Cancer Research. 2025-12-15
Press Mentions
Bristol Myers Squibb Research at ESMO 2021 Demonstrates Clinical Benefits of Immunotherapies in Multiple Hard-to-Treat Advanced or Metastatic Cancers and Reinforces the Benefit of Opdivo in Earlier-Stage CancersSeptember 8th, 2021
Northwestern Memorial Hospital Studying Arthritis Drug's Potential in Fighting CancerJuly 3rd, 2003
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
